Nov 19, 2018
Amyloidosis Treatment Market Worth $6.7 Billion by 2025 | CAGR: 7.2%: Grand View Research, Inc.
Nov 13, 2018
Global $6.7 Billion Amyloidosis Treatment Market to 2023 - Key Players are Alnylam, Ionis, Pfizer, Johnson & Johnson and Takeda
Nov 13, 2018
ProMIS Neurosciences Announces Third Quarter 2018 Results
Nov 06, 2018
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Oct 31, 2018
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
Oct 25, 2018
Mercaptor Announces the Appointment of World-Renowned Neuropathologist, Dr. Adriano Aguzzi to Scientific Advisory Board
Oct 18, 2018
R3 Stem Cell Now Offering Early Bird Discount for Regenerative Medicine Provider Training Course
Sep 12, 2018
Propanc Biopharma Provides Shareholder Update after Presenting at the 25th Annual NewsMakers in the Biotech Industry Conference
Aug 28, 2018
Dr. Joseph Banno Launches Online Training Program for Sexual Wellness
Jun 26, 2018
ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
May 11, 2018
ProMIS Neurosciences Announces First Quarter 2018 Results
Apr 05, 2018
Eidos Therapeutics completes $64M Series B financing
Mar 26, 2018
Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis
Mar 20, 2018
Eidos Therapeutics to Host Symposium on TTR Stabilization at the 16th International Symposium on Amyloidosis
Mar 14, 2018
Propanc Biopharma Completes Successful Reproduction Run for PRP
Mar 14, 2018
ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results
Mar 14, 2018
Reports indicate brain surgeons are at risk for transmitted Alzheimer's disease, says Dr. Leslie Norins on ALZgerm.org
Feb 16, 2018
Global Amyloidosis Market Spotlight 2017: Pfizer has Carried Out the Most Phase III Trials in Amyloidosis, Followed by Alnylam
Jan 23, 2018
Understanding The Pros And Cons Of PRP & Biologic Injections
Jan 04, 2018
ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies